Hey all, like many others it was a tough month for results. I cut a few smaller companies from the portfolio and added three new ones this month with SkyWater Technologies SKYT, Figure Technologies FIGR, and Evaxion EVAX.
This month I decided not to label the smaller companies “Microcap Ventures” because a few companies moved up in allocation to be normal positions, and a number of others disappointed which were sold. However, the basic idea stands that newer lower allocation positions are likely to get less attention. I also added a section on market commentary to the video this month detailing some thoughts on dealing with downturns in growth stocks.
Posted results at the end of November,
- 2024: +146%
- 2025: +104% YTD
- Cumulative return: +402%
Allocations at the end of November are,
- AppLovin APP - 20.5%
- Astera Labs ALAB - 19.8%
- Iren IREN - 17.8%
- Electrovaya ELVA - 11.2%
- Hive Digital Technologies HIVE - 9.6%
- Reddit RDDT - 4.6%
- Duos Technologies DUOT - 4.0%
- Dave Inc DAVE - 3.9%
- BioHarvest Sciences BHST - 3.5%
- Paymentus PAY - 1.4%
- SkyWater Technologies SKYT - 1.4%
- Figure Technologies FIGR - 1.3%
- Evaxion EVAX - 0.6%
- Organigram OGI - 0.6%
Promising new companies this month included six new companies and three companies we used to own that have piqued our interest again,
- Exzeo Group XZO - IPO spinoff for insurance SaaS platform
- Organogenesis ORGO - Biotech for skin substitutes, competitor to BioStem
- Telos Corporation TLS - SaaS security solutions primarily sold to the government
- Daily Journal Corporation DJCO - newspaper business with SaaS offering
- VusionGroup VU.PA - French IOT, cloud and data analytics business
- Adaptive Biotechnologies ADPT - genetic and clinical diagnostic solutions
- GeneDx WGS - genetic testing expanding to NICU + adult
- Amprius Technologies APMX - solid state battery company with business momentum
- Celestica CLS - hardware provider selling to hyperscalers and expanding to ASIC solutions
Any feedback on the holdings, new ideas or strategy is always welcome.